Related Experiment Videos
Different ataxin-2 antibodies display different immunoreactive profiles.
Victor J Turnbull1, Elsdon Storey, Volga Tarlac
1Van Cleef/Roet Centre for Nervous Diseases and Department of Neuroscience, Monash University (Alfred Hospital), Melbourne, Australia.
Brain Research
|October 21, 2004
Summary
A new antibody, 4A7, specifically targets ataxin-2, a protein linked to spinocerebellar ataxia type 2. This antibody reveals cell-specific localization of ataxin-2, offering insights into neurodegenerative disease mechanisms.
Area of Science:
- Neuroscience
- Molecular Biology
- Immunology
Background:
- Ataxin-2 protein is implicated in spinocerebellar ataxia type 2, a polyglutamine neurodegenerative disorder.
- Understanding ataxin-2 localization and interactions is crucial for neurodegenerative disease research.
Purpose of the Study:
- To develop and characterize a novel monoclonal antibody (4A7) against the C-terminus of ataxin-2.
- To investigate the subcellular localization and properties of ataxin-2 using the 4A7 antibody.
Main Methods:
- Monoclonal antibody development and characterization (4A7).
- Immunocytochemistry and subcellular fractionation in rat and primate cell lines.
- Western blotting and immunoprecipitation assays.
Main Results:
- The 4A7 antibody specifically recognizes ataxin-2, unlike a previously reported antibody (15F6).
- Ataxin-2 localizes to the cytoplasm and trans-Golgi network in rat cells but not primate cells.
- Ataxin-2 is phosphorylated, has a half-life of at least 21 hours, and its interactions are cell-type dependent.
Conclusions:
- The 4A7 antibody is a valuable tool for studying ataxin-2.
- Subcellular localization of ataxin-2 varies by host cell type.
- Ataxin-2 interactions are cell-specific, influencing its role in cellular processes and disease.